Skip to main content

Table 2 Baseline characteristics

From: Prevalence and abundance of selected genes conferring macrolide resistance genes in COPD patients during maintenance treatment with azithromycin

  Azithromycin group (n = 47) Placebo group
(n = 45)
Male 22 (46·8%) 18 (40%)
Age (years) 64·7 (10·2) 64·9 (10·2)
Current smoker 20 (43%) 9 (20%)
AECOPD in past year 4·0 (1·2) 4·0 (1·1)
Hospitalisation due to AECOPD 1·0 (1·1) 0·7 (0·8)
Spirometry after bronchodilation
FEV1(L) 1·1 (0·47) 1·1 (0·43)
FEV1(% of predicted) 44·2 (19·3) 45·0 (19·5)
FVC (L) 2·9 (0·8) 2·7 (0·92)
FVC (% of predicted) 92·5 (22·2) 88·9 (20·3)
FEV1/FVC (%) 38·0 (11·7) 40·3 (12·4)
GOLD stages
I 2 (4·3%) 3 (6·7%)
II 14 (29·8%) 12 (26·7%)
III 18 (38·3%) 20 (44·4%)
IV 13 (27·7%) 10 (22·2%)
  1. Data are in n (%) or mean (SD), unless otherwise stated. AECOPD = acute exacerbations of COPD. FEV1 Forced expiratory volume in 1 s. FVC Forced vital capacity. GOLD Global Initiative for Chronic Obstructive Pulmonary Disease